Botulinum toxin type A injection-related suppurative granuloma: a case report

Thanasarnaksorn, Wilai; Rattakul, Bheerathida; Suvanasuthi, Saroj; Sutthipisal, Nalinee

doi:10.1080/14764172.2019.1690663

Cited by 15 publications

(17 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the negative culture and polymerase chain reaction (PCR) results in the case they have presented, Thanasarnaksorn et al [4] suggested the role of non-tuberculous mycobacteria in the formation of such nodules. Other possibilities that have been suggested include preparation lubricant, diluent or components of the needle itself.…”

Section: Discussionmentioning

confidence: 99%

“…All patients were females and aged between 42 and 57 years old (mean 48.8 years). Medically two patients were diagnosed with sarcoidosis [2,3], another patient had hypertension [4], and the other two patients were fit and well. Across all the studies, the lesions presented at the same locations of the BoNT-A injections, and they appeared between two days and six years after treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Meanwhile, Ahbib et al [5] reported a case of sarcoid-like granuloma without foreign body involvement at the site of Botox® injections in a patient who had no signs of systemic sarcoidosis. Thanasarnaksorn et al [4] reported nodular eruption with histopathological findings of suppurative granuloma, which yielded negative results for all organisms on histochemical staining and tissue culture. In our presented case series, nodular eruptions developed between two days and three weeks after administration of Botox®; a timeframe which generally matched what is reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Nodular Eruptions as a Rare Complication of Botulinum Neurotoxin Type-A: Case Series and Review of Literature

Anabtawi¹,

Wege²,

Mahmood³

et al. 2020

Cureus

View full text Add to dashboard Cite

Nodular eruption after botulinum neurotoxin type-A (BoNT-A) treatment is exceedingly rare, and the pathogenesis is poorly understood. This case series reports three patients that developed nodular eruptions following administration of Botox® (onabotulinum neurotoxin type A (ONA) injections). These patients had undergone multiple treatments before and after development of the eruptions which were uneventful. In addition to this, we have reviewed the published literature regarding this condition and have compared and contrasted the similarities and differences with regards to the clinical presentation and treatment with our patient cohort. This case series aims to raise awareness of this rare condition, its importance in relation to patient consent and provides a simplified management approach based on our experience. Further evaluation is needed to determine treatment consensus but conducting such research may prove to be challenging due to this condition being an infrequent encounter.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Nodular Eruptions as a Rare Complication of Botulinum Neurotoxin Type-A: Case Series and Review of Literature

Anabtawi¹,

Wege²,

Mahmood³

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Few publications on granulomatous reactions at the BTXA injection sites exist. These granulomata can be of infectious origin or related to accidental inoculation by material eliciting a foreign body–like reaction, for example, from a BTXA diluent or lubricant material from the injection syringe 9‐11 …”

Section: Introductionmentioning

confidence: 99%

Botulinum toxin complications in registered and off‐label aesthetic indications

Landau

Nestor

Almeida

et al. 2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Botulinum toxin A (BTXA) is one of the most popular nonsurgical cosmetic procedures worldwide. Overall, this procedure is associated with favorable complications profile. Nevertheless, any medical intervention carries inherent risks. This synopsis systematically reviews adverse effects of aesthetic BTXA for both approved and off‐label indications. Based on published data, the approach for prevention and management is discussed.

show abstract